GSK struck an exclusive license with Empirico for an inhaled siRNA candidate targeting non‑type 2 inflammatory COPD, paying $85 million upfront and up to hundreds of millions in milestones. The deal is aimed at diversifying GSK’s respiratory portfolio with oligonucleotide modalities designed for long‑acting effects in patients poorly served by current therapies. GSK framed the transaction as complementary to its existing COPD assets and inhaled biologics strategy. Empirico retains program responsibility for the ongoing Phase 1 study while GSK will drive later-stage development and potential expansion into related respiratory conditions. The agreement signals renewed big‑pharma conviction in non‑traditional respiratory modalities and highlights continued interest in oligonucleotides outside hepatic indications.